

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10560928
Filing Date	2006-05-05
First Named Inventor	Yechezkel BARENHOLZ
Art Unit	1632
Examiner Name	Emily M. Le
Attorney Docket Number	BARENHOLZ 13

U.S.PATENTS						Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.						Add		
U.S.PATENT APPLICATION PUBLICATIONS						Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.						Add		
FOREIGN PATENT DOCUMENTS						Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button						Add		
NON-PATENT LITERATURE DOCUMENTS						Remove		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T ⁵	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		10560928
	Filing Date		2006-05-05
	First Named Inventor		Yechezkel BARENHOLZ
	Art Unit		1632
	Examiner Name		Emily M. Le
	Attorney Docket Number		BARENHOLZ 13

	1	Alving CR. Liposomes as adjuvants for vaccines. <i>Immunol Rev</i> 1995;145:5–31.	<input type="checkbox"/>
	2	Alving CR. Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity. <i>Ann NY Acad Sci</i> 1995;754:143–52.	<input type="checkbox"/>
	3	Babai et al. "A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice" <i>Vaccine</i> 1999;17:1223-38.	<input type="checkbox"/>
	4	Babai et al. "A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice" <i>Vaccine</i> 1999;17:1239-50.	<input type="checkbox"/>
	5	Cox et al. "Adjuvants—a classification and review of their modes of action" <i>Vaccine</i> 1997;15:248–56.	<input type="checkbox"/>
	6	Foged et al. "Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition" <i>Vaccine</i> 2004;22:1903–13.	<input type="checkbox"/>
	7	Garбуzenko et al. "Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer" <i>Chem Phys Lipids</i> 2005;135:117–29.	<input type="checkbox"/>
	8	Gregoriadis G. "The immunological adjuvant and vaccine carrier properties of liposomes" <i>J Drug Target</i> 1994;2:351–6	<input type="checkbox"/>
	9	Israelachvili et al. "Physical principles of membrane organization" <i>Q Rev Biophys</i> 1980;13:121–200.	<input type="checkbox"/>
	10	Itskovitz-Cooper et al. "A new intranasal influenza vaccine based on a novel polycationic lipid—ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice" <i>Vaccine</i> 2006;24:3990–4006.	<input type="checkbox"/>
	11	Laing et al. "The 'co-delivery' approach to liposomal vaccines: application to the development of influenza-A and hepatitis-B vaccine candidates" <i>J Liposome Res</i> 2006;16:229–35.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		10560928
	Filing Date		2006-05-05
	First Named Inventor		Yechezkel BARENHOLZ
	Art Unit		1632
	Examiner Name		Emily M. Le
	Attorney Docket Number		BARENHOLZ 13

	12	Lonez et al. "Cationic liposomal lipids: from gene carriers to cell signaling" Prog Lipid Res 2008;47:340–7.	<input type="checkbox"/>
	13	Miller et al. "Liposome–cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes" Biochemistry 1998;37:12875–83.	<input type="checkbox"/>
	14	Nakanishi et al."Positively charged liposome functions as an efficient immunoadjuvant in inducingimmuneresponses to soluble proteins" Biochem Biophys Res Commun 1997;240:793–7.	<input type="checkbox"/>
	15	Perrie et al. "Liposome-mediated DNA vaccination: the effect of vesicle composition" Vaccine 2001;19:3301–10.	<input type="checkbox"/>
	16	Schwendener et al. "The effects of charge and size on the interaction of unilamellar liposomes with macrophages" Biochim Biophys Acta 1984;772:93–101.	<input type="checkbox"/>
	17	Simberg et al. "DOTAP (and other cationic lipids): chemistry, biophysics, and transfection" Crit Rev Ther Drug Carrier Syst 2004;21(4):257–317.	<input type="checkbox"/>
	18	Storm et al. "Liposomes: quo vadis?" Pharm Sci Technol Today 1998;1:19–31.	<input type="checkbox"/>
	19	Yan et al. "Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines" Mol Immunol 2007;44:3672–81.	<input type="checkbox"/>
	20	Zhou et al. "Liposome-mediated cytoplasmic delivery of proteins: an effective means of accessing the MHC class I-restricted antigen presentation pathway" Immunomethods 1994;4:229–35. (Abstract Only)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Agnieszka Boesen/ (10/24/2011)	Date Considered	10/24/2011
--------------------	---------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10560928
	Filing Date	2006-05-05
	First Named Inventor	Yechezkel BARENHOLZ
	Art Unit	1632
	Examiner Name	Emily M. Le
	Attorney Docket Number	BARENHOLZ 13

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

/Agnieszka Boesen/ (10/24/2011)

10/24/2011